The American Academy of Neurology (AAN) has developed a new systematic review to summarize for neurologists and other ...

The American Academy of Neurology (AAN) has developed a new systematic review to summarize for neurologists and other ...

AnaptysBio may have ended last year on a low, but 2025 is looking up with the news that its PD-1 agonist rosnilimab has ...

Indian scientists have created an innovative self-actuating drug delivery system for Rheumatoid Arthritis, providing precise ...

Understand RA from early to advanced stages. Explore symptoms, treatments, and lifestyle tips to manage rheumatoid arthritis ...

Arthritis and bursitis are common joint pain causes, but differ in origin and treatment. Arthritis inflames joints due to ...

Nov. 13, 2024 — The use of biologic and targeted therapies for children with juvenile idiopathic arthritis (JIA) surpassed more typical therapies in recent years, ...

Gene therapies to treat rheumatoid arthritis have evolved slowly, but one is ready to move into human trials and an ...

People dealing with Rheumatoid Arthritis (RA) often face various challenges, such as pain and fatigue. But did you know they ...

Rheumatoid arthritis (RA) is an autoimmune disorder affecting millions worldwide, causing chronic inflammation, debilitating ...

The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both intravenous and subcutaneous formulations, according to a press release.

Avtozma, the third biosimilar to Actemra, has received FDA approval for multiple inflammatory diseases and COVID-19, ...